NAMS Menopause Exam Prep 2026 | Certified Menopause
Practitioner Practice Questions, Study Guide & Detailed Rationales
1. A 52-year-old woman reports severe hot flashes interfering with sleep. She has a history of
breast cancer treated with lumpectomy and radiation 5 years ago. Which treatment option is most
appropriate for managing her vasomotor symptoms?
A) Oral conjugated equine estrogens 0.625 mg daily
B) Transdermal estradiol 0.05 mg patch twice weekly
C) Low-dose paroxetine 7.5 mg daily
D) Estradiol vaginal ring 2 mg
E) Combination estrogen-progestin therapy
Correct Answer: C) Low-dose paroxetine 7.5 mg daily
Rationale: Low-dose paroxetine is FDA-approved for non-hormonal management of VMS and is
appropriate in breast cancer survivors. Estrogen therapy is generally contraindicated in women with
a history of breast cancer unless discussed with oncology. The vaginal ring provides primarily local
effects and may not adequately address systemic VMS.
2. A 48-year-old woman has experienced 60 consecutive days of amenorrhea. According to STRAW
criteria, which stage best describes her menopausal status?
A) Stage -2 (early menopause transition)
B) Stage -1 (late menopause transition)
C) Stage 0 (final menstrual period)
D) Stage +1a (early postmenopause)
E) Stage +2 (late postmenopause)
Correct Answer: B) Stage -1 (late menopause transition)
Rationale: STRAW criteria define stage -1 as the late menopause transition, characterized by 60 or
more days of amenorrhea. Stage -2 involves persistent cycle length differences of ≥7 days. Stage 0 is
the FMP itself, and stages +1a through +1c represent early postmenopause.
3. A 38-year-old woman presents with amenorrhea for 5 months and FSH levels of 32 mIU/mL and
28 mIU/mL drawn 5 weeks apart. What is the most likely diagnosis?
A) Perimenopause
B) Premature ovarian insufficiency
C) Hypothalamic amenorrhea
D) Polycystic ovary syndrome
E) Thyroid dysfunction
Correct Answer: B) Premature ovarian insufficiency
Rationale: POI is diagnosed in women under age 40 with amenorrhea ≥4 months and elevated FSH
>25 mIU/mL on two occasions at least 4 weeks apart. This patient meets all criteria. Perimenopause
occurs at the typical age, not under 40.
,4. Which laboratory finding is most consistent with the diagnosis of primary ovarian insufficiency?
A) FSH 12 mIU/mL, estradiol 80 pg/mL
B) FSH 8 mIU/mL, AMH 2.5 ng/mL
C) FSH 35 mIU/mL, estradiol 15 pg/mL
D) FSH 6 mIU/mL, inhibin B 45 pg/mL
E) FSH 18 mIU/mL, progesterone 12 ng/mL
Correct Answer: C) FSH 35 mIU/mL, estradiol 15 pg/mL
Rationale: POI is characterized by elevated FSH (>25 mIU/mL) and low estradiol levels due to ovarian
failure. The other options show normal or only mildly elevated FSH with adequate estradiol levels,
which would not support a diagnosis of POI.
5. A 55-year-old woman has a T-score of -2.8 at the lumbar spine. She has no history of fragility
fractures. Which medication would be most appropriate as initial therapy?
A) Raloxifene 60 mg daily
B) Alendronate 70 mg weekly
C) Teriparatide 20 mcg daily
D) Calcitonin nasal spray
E) Calcium carbonate 1500 mg daily
Correct Answer: B) Alendronate 70 mg weekly
Rationale: Bisphosphonates like alendronate are first-line therapy for postmenopausal osteoporosis
with a T-score < -2.5. Raloxifene is generally used for women with lower fracture risk or those at high
risk for breast cancer. Teriparatide is reserved for very high-risk patients, and calcitonin is less
effective.
6. What is the median age of natural menopause in US women?
A) 48.5 years
B) 50.2 years
C) 52.5 years
D) 54.8 years
E) 56.1 years
Correct Answer: C) 52.5 years
Rationale: The median age of natural menopause in US women is 52.5 years. Early menopause is
defined as age <45 years, and late menopause as age >54 years. The range of normal is typically 45-
55 years.
7. A 62-year-old woman on alendronate for 5 years has a new T-score of -2.4 at the femoral neck.
What is the most appropriate management?
A) Continue alendronate indefinitely
B) Start a drug holiday
C) Switch to teriparatide
,D) Add raloxifene
E) Discontinue all osteoporosis medications
Correct Answer: B) Start a drug holiday
Rationale: After 5 years of bisphosphonate therapy, a drug holiday may be considered if the patient
no longer meets criteria for treatment (T-score > -2.5 and no fractures). This patient's T-score is now -
2.4, which is in the osteopenic range, supporting a drug holiday with monitoring.
8. Which ethnic group has the highest prevalence and severity of vasomotor symptoms during
menopause?
A) Caucasian women
B) Hispanic women
C) Asian women
D) Black women
E) Native American women
Correct Answer: D) Black women
Rationale: Black women experience the highest prevalence and severity of VMS, with more frequent
and longer-lasting hot flashes. Japanese women have the lowest prevalence of VMS. Hispanic and
Caucasian women have intermediate rates.
9. A 50-year-old woman with a uterus reports heavy menstrual bleeding. Her endometrial biopsy
shows no hyperplasia. Which hormonal therapy would provide the lowest risk of endometrial
stimulation while managing her bleeding?
A) Oral conjugated estrogens 0.625 mg daily with medroxyprogesterone 2.5 mg daily
B) Estradiol patch 0.05 mg with micronized progesterone 100 mg daily
C) Estradiol patch 0.05 mg with micronized progesterone 200 mg for 12 days monthly
D) Oral conjugated estrogens 0.3 mg daily without progestin
E) Estradiol vaginal ring 2 mg
Correct Answer: C) Estradiol patch 0.05 mg with micronized progesterone 200 mg for 12 days
monthly
Rationale: For women with a uterus, cyclic progestin (12-14 days/month) is recommended to prevent
endometrial hyperplasia. Continuous combined therapy (option B) is also appropriate but option C
specifically addresses the heavy bleeding with a cyclic progestin regimen.
10. Which non-hormonal medication is FDA-approved specifically for the treatment of vasomotor
symptoms?
A) Venlafaxine 75 mg daily
B) Gabapentin 300 mg three times daily
C) Low-dose paroxetine 7.5 mg daily
D) Clonidine 0.1 mg daily
E) Oxybutynin 5 mg daily
Correct Answer: C) Low-dose paroxetine 7.5 mg daily
, Rationale: Low-dose paroxetine (Brisdelle) is the only SSRI specifically FDA-approved for VMS at this
dosage. The other medications are used off-label for VMS management. Fezolinetant and
elinzanetant are also FDA-approved non-hormonal options.
11. A 47-year-old woman reports irregular periods with cycle length varying by 8-10 days over the
past 6 months. According to STRAW staging, what stage is she in?
A) Stage -5 (early reproductive)
B) Stage -3b (late reproductive)
C) Stage -2 (early menopause transition)
D) Stage -1 (late menopause transition)
E) Stage +1a (early postmenopause)
Correct Answer: C) Stage -2 (early menopause transition)
Rationale: Stage -2 is defined by persistent differences of ≥7 days in consecutive cycle lengths. This
represents the early menopause transition. Stage -1 is characterized by ≥60 days of amenorrhea.
12. Which screening test is most appropriate for osteoporosis in a 66-year-old woman?
A) Quantitative ultrasound of the calcaneus
B) Dual-energy x-ray absorptiometry of the hip and spine
C) Peripheral DXA of the wrist
D) CT scan of the lumbar spine
E) X-ray of the lateral thoracic and lumbar spine
Correct Answer: B) Dual-energy x-ray absorptiometry of the hip and spine
Rationale: Central DXA of the hip and spine is the gold standard for diagnosing osteoporosis. All
women ≥65 years should have a DXA. Peripheral screening tests may be used but are less accurate
and not diagnostic.
13. A 58-year-old woman with breast cancer on an aromatase inhibitor reports vaginal dryness
and dyspareunia. What is the safest initial treatment option?
A) Vaginal estrogen cream twice weekly
B) Vaginal prasterone (DHEA) insert daily
C) Systemic estrogen therapy
D) Ospemifene 60 mg daily
E) Vaginal lubricants and moisturizers
Correct Answer: E) Vaginal lubricants and moisturizers
Rationale: Non-hormonal lubricants and moisturizers are the first-line treatment for GSM. If
symptoms persist, low-dose vaginal estrogen or prasterone may be considered after discussion with
oncology. Systemic estrogen and ospemifene are generally avoided in breast cancer patients.
14. What is the most common cause of abnormal uterine bleeding in perimenopausal women?
A) Endometrial polyps
Practitioner Practice Questions, Study Guide & Detailed Rationales
1. A 52-year-old woman reports severe hot flashes interfering with sleep. She has a history of
breast cancer treated with lumpectomy and radiation 5 years ago. Which treatment option is most
appropriate for managing her vasomotor symptoms?
A) Oral conjugated equine estrogens 0.625 mg daily
B) Transdermal estradiol 0.05 mg patch twice weekly
C) Low-dose paroxetine 7.5 mg daily
D) Estradiol vaginal ring 2 mg
E) Combination estrogen-progestin therapy
Correct Answer: C) Low-dose paroxetine 7.5 mg daily
Rationale: Low-dose paroxetine is FDA-approved for non-hormonal management of VMS and is
appropriate in breast cancer survivors. Estrogen therapy is generally contraindicated in women with
a history of breast cancer unless discussed with oncology. The vaginal ring provides primarily local
effects and may not adequately address systemic VMS.
2. A 48-year-old woman has experienced 60 consecutive days of amenorrhea. According to STRAW
criteria, which stage best describes her menopausal status?
A) Stage -2 (early menopause transition)
B) Stage -1 (late menopause transition)
C) Stage 0 (final menstrual period)
D) Stage +1a (early postmenopause)
E) Stage +2 (late postmenopause)
Correct Answer: B) Stage -1 (late menopause transition)
Rationale: STRAW criteria define stage -1 as the late menopause transition, characterized by 60 or
more days of amenorrhea. Stage -2 involves persistent cycle length differences of ≥7 days. Stage 0 is
the FMP itself, and stages +1a through +1c represent early postmenopause.
3. A 38-year-old woman presents with amenorrhea for 5 months and FSH levels of 32 mIU/mL and
28 mIU/mL drawn 5 weeks apart. What is the most likely diagnosis?
A) Perimenopause
B) Premature ovarian insufficiency
C) Hypothalamic amenorrhea
D) Polycystic ovary syndrome
E) Thyroid dysfunction
Correct Answer: B) Premature ovarian insufficiency
Rationale: POI is diagnosed in women under age 40 with amenorrhea ≥4 months and elevated FSH
>25 mIU/mL on two occasions at least 4 weeks apart. This patient meets all criteria. Perimenopause
occurs at the typical age, not under 40.
,4. Which laboratory finding is most consistent with the diagnosis of primary ovarian insufficiency?
A) FSH 12 mIU/mL, estradiol 80 pg/mL
B) FSH 8 mIU/mL, AMH 2.5 ng/mL
C) FSH 35 mIU/mL, estradiol 15 pg/mL
D) FSH 6 mIU/mL, inhibin B 45 pg/mL
E) FSH 18 mIU/mL, progesterone 12 ng/mL
Correct Answer: C) FSH 35 mIU/mL, estradiol 15 pg/mL
Rationale: POI is characterized by elevated FSH (>25 mIU/mL) and low estradiol levels due to ovarian
failure. The other options show normal or only mildly elevated FSH with adequate estradiol levels,
which would not support a diagnosis of POI.
5. A 55-year-old woman has a T-score of -2.8 at the lumbar spine. She has no history of fragility
fractures. Which medication would be most appropriate as initial therapy?
A) Raloxifene 60 mg daily
B) Alendronate 70 mg weekly
C) Teriparatide 20 mcg daily
D) Calcitonin nasal spray
E) Calcium carbonate 1500 mg daily
Correct Answer: B) Alendronate 70 mg weekly
Rationale: Bisphosphonates like alendronate are first-line therapy for postmenopausal osteoporosis
with a T-score < -2.5. Raloxifene is generally used for women with lower fracture risk or those at high
risk for breast cancer. Teriparatide is reserved for very high-risk patients, and calcitonin is less
effective.
6. What is the median age of natural menopause in US women?
A) 48.5 years
B) 50.2 years
C) 52.5 years
D) 54.8 years
E) 56.1 years
Correct Answer: C) 52.5 years
Rationale: The median age of natural menopause in US women is 52.5 years. Early menopause is
defined as age <45 years, and late menopause as age >54 years. The range of normal is typically 45-
55 years.
7. A 62-year-old woman on alendronate for 5 years has a new T-score of -2.4 at the femoral neck.
What is the most appropriate management?
A) Continue alendronate indefinitely
B) Start a drug holiday
C) Switch to teriparatide
,D) Add raloxifene
E) Discontinue all osteoporosis medications
Correct Answer: B) Start a drug holiday
Rationale: After 5 years of bisphosphonate therapy, a drug holiday may be considered if the patient
no longer meets criteria for treatment (T-score > -2.5 and no fractures). This patient's T-score is now -
2.4, which is in the osteopenic range, supporting a drug holiday with monitoring.
8. Which ethnic group has the highest prevalence and severity of vasomotor symptoms during
menopause?
A) Caucasian women
B) Hispanic women
C) Asian women
D) Black women
E) Native American women
Correct Answer: D) Black women
Rationale: Black women experience the highest prevalence and severity of VMS, with more frequent
and longer-lasting hot flashes. Japanese women have the lowest prevalence of VMS. Hispanic and
Caucasian women have intermediate rates.
9. A 50-year-old woman with a uterus reports heavy menstrual bleeding. Her endometrial biopsy
shows no hyperplasia. Which hormonal therapy would provide the lowest risk of endometrial
stimulation while managing her bleeding?
A) Oral conjugated estrogens 0.625 mg daily with medroxyprogesterone 2.5 mg daily
B) Estradiol patch 0.05 mg with micronized progesterone 100 mg daily
C) Estradiol patch 0.05 mg with micronized progesterone 200 mg for 12 days monthly
D) Oral conjugated estrogens 0.3 mg daily without progestin
E) Estradiol vaginal ring 2 mg
Correct Answer: C) Estradiol patch 0.05 mg with micronized progesterone 200 mg for 12 days
monthly
Rationale: For women with a uterus, cyclic progestin (12-14 days/month) is recommended to prevent
endometrial hyperplasia. Continuous combined therapy (option B) is also appropriate but option C
specifically addresses the heavy bleeding with a cyclic progestin regimen.
10. Which non-hormonal medication is FDA-approved specifically for the treatment of vasomotor
symptoms?
A) Venlafaxine 75 mg daily
B) Gabapentin 300 mg three times daily
C) Low-dose paroxetine 7.5 mg daily
D) Clonidine 0.1 mg daily
E) Oxybutynin 5 mg daily
Correct Answer: C) Low-dose paroxetine 7.5 mg daily
, Rationale: Low-dose paroxetine (Brisdelle) is the only SSRI specifically FDA-approved for VMS at this
dosage. The other medications are used off-label for VMS management. Fezolinetant and
elinzanetant are also FDA-approved non-hormonal options.
11. A 47-year-old woman reports irregular periods with cycle length varying by 8-10 days over the
past 6 months. According to STRAW staging, what stage is she in?
A) Stage -5 (early reproductive)
B) Stage -3b (late reproductive)
C) Stage -2 (early menopause transition)
D) Stage -1 (late menopause transition)
E) Stage +1a (early postmenopause)
Correct Answer: C) Stage -2 (early menopause transition)
Rationale: Stage -2 is defined by persistent differences of ≥7 days in consecutive cycle lengths. This
represents the early menopause transition. Stage -1 is characterized by ≥60 days of amenorrhea.
12. Which screening test is most appropriate for osteoporosis in a 66-year-old woman?
A) Quantitative ultrasound of the calcaneus
B) Dual-energy x-ray absorptiometry of the hip and spine
C) Peripheral DXA of the wrist
D) CT scan of the lumbar spine
E) X-ray of the lateral thoracic and lumbar spine
Correct Answer: B) Dual-energy x-ray absorptiometry of the hip and spine
Rationale: Central DXA of the hip and spine is the gold standard for diagnosing osteoporosis. All
women ≥65 years should have a DXA. Peripheral screening tests may be used but are less accurate
and not diagnostic.
13. A 58-year-old woman with breast cancer on an aromatase inhibitor reports vaginal dryness
and dyspareunia. What is the safest initial treatment option?
A) Vaginal estrogen cream twice weekly
B) Vaginal prasterone (DHEA) insert daily
C) Systemic estrogen therapy
D) Ospemifene 60 mg daily
E) Vaginal lubricants and moisturizers
Correct Answer: E) Vaginal lubricants and moisturizers
Rationale: Non-hormonal lubricants and moisturizers are the first-line treatment for GSM. If
symptoms persist, low-dose vaginal estrogen or prasterone may be considered after discussion with
oncology. Systemic estrogen and ospemifene are generally avoided in breast cancer patients.
14. What is the most common cause of abnormal uterine bleeding in perimenopausal women?
A) Endometrial polyps
